NASDAQ: MGXMetagenomi Inc Stock
$6.54-0.01 (-0.15%)
Updated May 14, 2024
MGX Price
$6.54
Fair Value Price
N/A
Market Cap
$245.02M
52 Week Low
$5.50
52 Week High
$12.74
P/E
N/A
P/B
0.89x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.51
Operating Cash Flow
N/A
Beta
2.64
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MGX Overview
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.
Zen Score
–
Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MGX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MGX is good value based on its book value relative to its share price (0.89x), compared to the US Biotechnology industry average (6.05x)
P/B vs Industry Valuation
MGX's short-term assets ($335.64M) exceed its short-term liabilities ($70.70M)
Short-term Liabilities Financials
MGX's short-term assets ($335.64M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more MGX due diligence checks available for Premium users.
Be the first to know about important MGX news, forecast changes, insider trades & much more!
MGX News
Valuation
MGX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.89x
Industry
6.05x
MGX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MGX's financial health
Profit margin
Revenue
$11.2M
Net Income
-$25.1M
Profit Margin
-225.4%
Assets to liabilities
Assets
$415.4M
Liabilities
$139.8M
Debt to equity
0.51
MGX's short-term assets ($335.64M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MGX's short-term assets ($335.64M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MGX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$29.9M
Investing
-$94.7M
Financing
$86.5M
MGX vs Biotech Stocks
Metagenomi Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.